Walleye Capital LLC - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 188 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2021. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.

Quarter-by-quarter ownership
Walleye Capital LLC ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$7,811,156
+711.6%
149,955
+886.5%
0.02%
+566.7%
Q2 2023$962,464
-92.2%
15,200
-93.3%
0.00%
-98.4%
Q1 2023$12,346,308
+0.9%
228,002
-1.4%
0.18%
-17.0%
Q4 2022$12,241,031
+10.6%
231,312
-2.8%
0.22%
+5.2%
Q3 2022$11,068,000
+99.1%
237,863
+144.2%
0.21%
+38.6%
Q2 2022$5,560,000
+30.3%
97,410
+39.7%
0.15%
+34.2%
Q1 2022$4,266,000
+355.8%
69,719
+290.0%
0.11%
+293.1%
Q4 2021$936,000
-76.0%
17,878
-82.9%
0.03%
-73.6%
Q3 2021$3,893,000
+8.8%
104,425
+19.1%
0.11%
-9.8%
Q2 2021$3,578,000
+64.7%
87,653
+36.8%
0.12%
-3.2%
Q1 2021$2,173,000
+4.5%
64,054
-2.1%
0.13%
-9.4%
Q4 2020$2,080,000
-72.5%
65,400
-70.3%
0.14%
-71.6%
Q4 2019$7,561,000
+742.0%
220,368
+83.3%
0.49%
+824.5%
Q3 2019$898,000
+519.3%
120,200
+901.2%
0.05%
+120.8%
Q1 2019$145,00012,0050.02%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q2 2021
NameSharesValueWeighting ↓
TANG CAPITAL MANAGEMENT LLC 700,000$42,833,0008.57%
SILVERARC CAPITAL MANAGEMENT, LLC 308,819$18,897,0007.82%
Vahanian & Associates Financial Planning Inc. 45,533$2,786,0006.44%
DCF Advisers, LLC 238,500$14,594,0006.39%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 50,956$20,930,0004.72%
SUVRETTA CAPITAL MANAGEMENT, LLC 1,531,923$93,738,0002.86%
Nicholas Investment Partners, LP 562,373$34,412,0002.45%
Bellevue Group AG 3,429,619$209,859,0002.44%
WASATCH ADVISORS LP 7,477,868$457,571,0002.25%
Quantum Private Wealth, LLC 73,772$4,514,0001.95%
View complete list of INTRA CELLULAR THERAPIES INC shareholders